| Oct 10 |
Seres Therapeutics gains amid takeover speculation
|
| Oct 8 |
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
|
| Oct 1 |
Seres Therapeutics files for resale of common stock by holder
|
| Sep 30 |
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
|
| Sep 26 |
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
|
| Sep 23 |
Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
|
| Sep 13 |
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
|
| Sep 12 |
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
|
| Sep 6 |
Seres Therapeutics jumps on report of Nestle acquisition offer
|
| Sep 4 |
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
|
